Retatrutide and blood pressure — need advice

dave_SLC said:

I'm 67 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Thank you for spelling out the reasoning rather than just the conclusion. Adding it to my notes with a link back to this thread.

Clinical perspective, offered as context rather than as advice.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

Dr.SurgeonPGH said:

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Adding a me-too, because a thread of one person's experience is not much use. I had assumed I was the exception until I read this.

Dr.SurgeonPGH said:

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

Dr.SurgeonPGH said:

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 14 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 53" → 37" ✅ Resolved
2. Triglycerides: 231 → 101 ✅ Resolved
3. HDL: 37 → 53 ✅ Resolved
4. Blood pressure: 141/97 → 119/73 ✅ Resolved
5. Fasting glucose: 126 → 89 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.